177 related articles for article (PubMed ID: 19465119)
1. Drug release from MCC- and carrageenan-based pellets: experiment and theory.
Kranz H; Jürgens K; Pinier M; Siepmann J
Eur J Pharm Biopharm; 2009 Oct; 73(2):302-9. PubMed ID: 19465119
[TBL] [Abstract][Full Text] [Related]
2. Use of kappa-carrageenan as alternative pelletisation aid to microcrystalline cellulose in extrusion/spheronisation. II. Influence of drug and filler type.
Thommes M; Kleinebudde P
Eur J Pharm Biopharm; 2006 May; 63(1):68-75. PubMed ID: 16325384
[TBL] [Abstract][Full Text] [Related]
3. Suitability of κ-carrageenan pellets for the formulation of multiparticulate tablets with modified release.
Ghanam D; Kleinebudde P
Int J Pharm; 2011 May; 409(1-2):9-18. PubMed ID: 21335073
[TBL] [Abstract][Full Text] [Related]
4. Use of kappa-carrageenan as alternative pelletisation aid to microcrystalline cellulose in extrusion/spheronisation. I. Influence of type and fraction of filler.
Thommes M; Kleinebudde P
Eur J Pharm Biopharm; 2006 May; 63(1):59-67. PubMed ID: 16326085
[TBL] [Abstract][Full Text] [Related]
5. Influence of MCC II fraction and storage conditions on pellet properties.
Krueger C; Thommes M; Kleinebudde P
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1039-45. PubMed ID: 23872176
[TBL] [Abstract][Full Text] [Related]
6. Effect of drying on extruded pellets based on kappa-carrageenan.
Thommes M; Blaschek W; Kleinebudde P
Eur J Pharm Sci; 2007 Jun; 31(2):112-8. PubMed ID: 17448646
[TBL] [Abstract][Full Text] [Related]
7. Multiple batch manufacturing of theophylline pellets using the wet-extrusion/spheronization process with κ-carrageenan as pelletisation aid.
Krueger C; Thommes M
Pharm Dev Technol; 2013 Feb; 18(1):225-35. PubMed ID: 22780876
[TBL] [Abstract][Full Text] [Related]
8. Controlled drug release from Gelucire-based matrix pellets: experiment and theory.
Siepmann F; Muschert S; Flament MP; Leterme P; Gayot A; Siepmann J
Int J Pharm; 2006 Jul; 317(2):136-43. PubMed ID: 16621362
[TBL] [Abstract][Full Text] [Related]
9. Drug release mechanisms from ethylcellulose: PVA-PEG graft copolymer-coated pellets.
Muschert S; Siepmann F; Leclercq B; Carlin B; Siepmann J
Eur J Pharm Biopharm; 2009 May; 72(1):130-7. PubMed ID: 19146955
[TBL] [Abstract][Full Text] [Related]
10. Production of pellets via extrusion-spheronisation without the incorporation of microcrystalline cellulose: a critical review.
Dukić-Ott A; Thommes M; Remon JP; Kleinebudde P; Vervaet C
Eur J Pharm Biopharm; 2009 Jan; 71(1):38-46. PubMed ID: 18771727
[TBL] [Abstract][Full Text] [Related]
11. The use of partially hydrolysed polyvinyl alcohol for the production of high drug-loaded sustained release pellets via extrusion-spheronisation and coating: In vitro and in vivo evaluation.
Verstraete G; De Jaeghere W; Vercruysse J; Grymonpré W; Vanhoorne V; Stauffer F; De Beer T; Bezuijen A; Remon JP; Vervaet C
Int J Pharm; 2017 Jan; 517(1-2):88-95. PubMed ID: 27919698
[TBL] [Abstract][Full Text] [Related]
12. Incidence of drying on microstructure and drug release profiles from tablets of MCC-lactose-Carbopol and MCC-dicalcium phosphate-Carbopol pellets.
Gómez-Carracedo A; Souto C; Marti Nez-Pacheco R; Concheiro A; Gómez-Amoza JL
Eur J Pharm Biopharm; 2008 Jun; 69(2):675-85. PubMed ID: 18248805
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of microcrystalline cellulose II (MCCII) as an alternative extrusion-spheronization aid.
Rojas J; Kumar V
Pharmazie; 2012 Jul; 67(7):595-7. PubMed ID: 22888514
[TBL] [Abstract][Full Text] [Related]
14. Improved bioavailability of darunavir by use of kappa-carrageenan versus microcrystalline cellulose as pelletisation aid.
Thommes M; Baert L; van 't Klooster G; Geldof M; Schueller L; Rosier J; Kleinebudde P
Eur J Pharm Biopharm; 2009 Aug; 72(3):614-20. PubMed ID: 19303929
[TBL] [Abstract][Full Text] [Related]
15. Influence of storage condition on properties of MCC II-based pellets with theophylline-monohydrate.
Krueger C; Thommes M; Kleinebudde P
Eur J Pharm Biopharm; 2014 Oct; 88(2):483-91. PubMed ID: 24950003
[TBL] [Abstract][Full Text] [Related]
16. Use of crospovidone as pelletization aid as alternative to microcrystalline cellulose: effects on pellet properties.
Verheyen P; Steffens KJ; Kleinebudde P
Drug Dev Ind Pharm; 2009 Nov; 35(11):1325-32. PubMed ID: 19832632
[TBL] [Abstract][Full Text] [Related]
17. Wax-based sustained release matrix pellets prepared by a novel freeze pelletization technique II. In vitro drug release studies and release mechanisms.
Cheboyina S; Wyandt CM
Int J Pharm; 2008 Jul; 359(1-2):167-73. PubMed ID: 18495391
[TBL] [Abstract][Full Text] [Related]
18. Control of drug release by incorporation of sorbitol or mannitol in microcrystalline-cellulose-based pellets prepared by extrusion-spheronization.
Goyanes A; Souto C; Martínez-Pacheco R
Pharm Dev Technol; 2010 Dec; 15(6):626-35. PubMed ID: 20148708
[TBL] [Abstract][Full Text] [Related]
19. Release behaviour of clozapine matrix pellets based on percolation theory.
Aguilar-de-Leyva A; Sharkawi T; Bataille B; Baylac G; Caraballo I
Int J Pharm; 2011 Feb; 404(1-2):133-41. PubMed ID: 21094234
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the drug release patterns and long term stability of aqueous and organic coated pellets by using blends of enteric and gastrointestinal insoluble polymers.
Kranz H; Gutsche S
Int J Pharm; 2009 Oct; 380(1-2):112-9. PubMed ID: 19632313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
